Programme Thesis
Emergent Ventures is Tyler Cowen's personal talent-spotting fellowship at the Mercatus Center (GMU), funded partly by Peter Thiel, that backs 'zero to one' projects — ideas too speculative, contrarian, or cross-disciplinary to be funded by conventional academic grants or venture capital. It exists because Cowen believes the world systematically under-invests in unusual early-stage talent and that short, unbureaucratic grants to the right people can generate outsized returns. Grants range from $1K to $50K+; the application is intentionally minimal and rolling, read personally by Cowen.
Selection Criteria
• **Zero-to-one originality**: The core filter — is this genuinely novel, or incremental? Cowen explicitly deprioritises projects that could get funded elsewhere.
• **Unusual talent signal**: Evidence the applicant is an outlier — not pedigree per se, but demonstrated capability, intellectual range, and drive (papers, platforms, patents, endorsements from serious people).
• **Can't-get-funded-elsewhere test**: Pre-revenue, pre-institutional, speculative or cross-disciplinary work is preferred over anything that a standard NSF/NIH grant or seed fund would touch.
• **Revenue or commercialisation path (a plus, not a requirement)**: EV explicitly notes for-profit is fine and a quick path to revenue is a positive signal — but research-only applications are accepted.
• **Brief, vivid application**: Cowen reads thousands; clarity and distinctiveness of writing signals intelligence. Verbose academic prose is a negative signal.
• **Track eligibility**: Dedicated Africa, India, Caribbean, and Ukraine tracks exist; track applicants compete within their cohort, not globally.
• **Age 13+ from anywhere**: No residency, degree, or company required — deliberately low barriers.
Past Winners / Cohort Profiles
EV has funded ~400+ grants since 2018 across a deliberately eclectic range. Named archetypes from public announcements on Cowen's Marginal Revolution blog include: (1) independent researchers and bloggers doing serious science outside academia (e.g. Gwern Branwen, rationalist/ML researcher); (2) precocious students with one contrarian idea (high-school students through early postgrads); (3) Africa/India track entrepreneurs building category-new tools for their local markets; (4) AI safety researchers before the field was mainstream; (5) science writers, policy thinkers, and 'intellectual entrepreneurs' who defy easy categorisation. The Africa track has supported Lagos- and Nairobi-based founders in health-tech, edtech, and computational research. The common thread across all cohorts is that Cowen announces them with a one-sentence summary that makes the bet seem obvious in retrospect — the aha-moment framing is by design.
Ideal Candidate Fingerprint
The platonic EV winner is someone Cowen could describe in one surprising sentence — an independent 27-year-old Lagos pharmacologist who built a Bayesian ODE model of addiction prevention and holds a provisional patent, endorsed by four named Ivy-plus neuroscientists, with a SaaS screening platform already live. They are early enough that no institution has claimed them yet, late enough to have proof of capability, and building something that no grant committee would approve because it crosses too many disciplinary lines. Revenue path is a bonus that converts a pure research bet into a safer one.
Recommended Framing
Eniola should open every section with IMPRINT as the hook — a Lagos-built addiction-liability screening SaaS that monetises a novel pharmacological insight (the CCT framework) no academic lab has published before, validated by Bayesian MCMC + ODE modelling and provisionally patented, with endorsements from Berridge, Gershman, Daw, and Mattar as the credibility layer. The Africa track removes her from global competition entirely. The 'zero to one' sentence to lead with: 'I built a tripartite pharmacological model that predicts addiction vulnerability before first use, validated it computationally, and am turning it into a SaaS screening tool from Lagos — without a PhD, without a lab, and without institutional funding.' Every form section should reinforce: the idea is original, the execution is real, the path to revenue exists, and this is precisely the bet no one else will take.
Watch Out
• **Award ceiling vs. target gap**: EV's typical range tops at $50K; Eniola's stated target is $10K–$100K. A $50K ask is at the programme's upper limit and should be explicitly budgeted (e.g. 12 months of compute, travel to conference, patent filing costs) — not left vague.
• **Academic over-writing risk**: The application must be short, punchy, and written for a general intellectual audience. CCT framing must avoid jargon-heavy neuropharmacology; Cowen values clarity and wit over technical depth in the application text itself.
• **'Research vs. founder' identity tension**: EV increasingly rewards the founder-researcher hybrid. Eniola should lean into IMPRINT as a product, not as a research output — commercialisation framing must feel genuine, not bolted on.
• **No enrolled PhD**: Not a disqualifier — EV explicitly backs pre-institutional talent — but the application should acknowledge the planned MUG/Graz MSc application as a deliberate next step, not a gap.
• **Preprints not yet peer-reviewed**: Two of three papers are preprints; the Zenodo paper is new (2026). Cowen is comfortable with preprints, but the application should highlight the Alcohol (Elsevier) co-authored paper under review as the peer-review signal.